Both sides fear undue influence on independent review of US FDA CTP

The tobacco industry has little faith that the upcoming external review of the Center for Tobacco Products (CTP) announced by US Food and Drug Administration (FDA) commissioner Robert Califf will help fix faults in the agency’s regulation of new tobacco and alternative products.

Industry representatives say the review, to be carried out by the agency’s partner organisation Reagan-Udall Foundation, is being launched at a time when delays and back-tracking in handling the pre-market tobacco application process (PMTA) for alternative tobacco products are all too evident and have already produced wide damage.

Read full article
I'm already a subscriber

Tiziana Cauli

Senior reporter/health & science editor
Tiziana is an Italian journalist from Sardinia. She has worked for both international and local media in Italy, South Africa, France, Spain, the UK, Lebanon and Belgium. She also worked as a communications manager for several international NGOs in the humanitarian sector. Tiziana holds a degree in Political Science and a PhD in African Studies from the University of Cagliari and she’s a graduate of the Carlo De Martino school of journalism in Milan.

Our Key Benefits

The global novel nicotine market is in an opaque regulatory environment that requires professionals to be on top of industry developments to make informed decisions and optimise their strategy.

TobaccoIntelligence provides organisations with leading market and regulatory data analysis to anticipate and understand market developments globally and the impact of regulatory changes to the business.

  • Stay informed of any legal and market change in the sector that impacts your organisation
  • Maximise resources by getting market and legal data analysis daily in one place
  • Make smart decisions by understanding how the regulatory and market landscape evolves
  • Anticipate risks in your decisions by monitoring regulatory changes that impact your organisation